1 : 2 5% prior ≥2 10 NR 50 22 / 14 50 % 5% prior ≥2 (A) (38%) NR 11 Median 70 53 28 : 16 Median of 2 trial treatments (A) (36%) 11 : 5 12 NR 42 11 : 10 Median of 3 prior treatments (A) (48%) NR 276 / 108 (28%) *: Publication or Abstract AA: Anaplastic Astrocytoma, AO: Anaplastic Oligoastrocytoma Pooled response rates were reported for all the groups except for group 10, which only reported PFS and OS. More than 5% of patients in the pooled analysis obtained a CR compared with < 1% in the 349 historic controls (Wong et al) (Table 14). Table 14 Summary of response efficacy data for Patient Groups 5-12 Patient Number Response Rates Group (combined Grade III and IV (A or P) n (all) Grade III n CR PR ORR (%) SD CR+PR PD (Grade III) 5 61 24 (40%) 7/53 PR 32/55 NR (P) AA = 15 SD 11/55 AO = 9 PD 3/55 6 55 22 (40%) 1/55 PR 25/55 NR (P) AG = 21 SD 25/55 Other = 1 PD 3/55 7 27 15 (55%) 0/27 PR 12/27 NR (P) Gd III = 9 SD 11/27
1 : 2 5% ≥2 prior 10 (A) NR 50 22 / 14 (38%) NR 50 % 5% ≥2 prior 11 (A) Median 70 53 28 : 16 (36%) 11 : 5 Median of 2 treatments 12 (A) NR 42 11 : 10 (48%) NR Median of 3 prior treatments 276 / 108 (28%) *: Publication or Abstract AA: Anaplastic Astrocytoma, AO: Anaplastic Oligoastrocytoma Pooled response rates were reported for all the groups except for group 10, which only reported PFS and OS. More than 5% of patients in the pooled analysis obtained a CR compared with < 1% in the 349 historic controls (Wong et al) (Table 14). Table 14 Summary of response efficacy data for Patient Groups 5-12 Patient Group (A or P) Number Response Rates (combined Grade III and IV n (all) Grade III n (%) CR PR SD PD ORR CR+PR (Grade III) 5 (P) 61 24 (40%) AA = 15 AO = 9 7/53 PR 32/55 SD 11/55 PD 3/55 NR 6 (P) 55 22 (40%) AG = 21 Other = 1 1/55 PR 25/55 SD 25/55 PD 3/55 NR 7 (P) 27 15 (55%) Gd III = 9 0/27 PR 12/27 SD 11/27 NR trial
auspar-bevacizumab-091214-01.docx